Cabazitaxel in Relapsed and Metastatic NSCLC

NCT01852578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Cabazitaxel

Sponsor

Hellenic Oncology Research Group